Fig. 3From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trialSubgroup analyses of change in eEV through week 24. eEV estimated extracellular volume. Others see Fig. 2Back to article page